Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment.
Tanaka S, Tamiya M, Nishiuma S, Nakamura S, Nozaki K, Watanabe N, Itoh C, Kadokawa Y, Takeda K, Takahashi K, Miyazaki A, Kawamura T, Kunimasa K, Inoue T, Nishino K, Takagi M.
Tanaka S, et al. Among authors: itoh c.
Cancer Treat Res Commun. 2024;40:100836. doi: 10.1016/j.ctarc.2024.100836. Epub 2024 Jul 30.
Cancer Treat Res Commun. 2024.
PMID: 39098310
Free article.